Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth…
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Painful diabetic neuropathy (PDN) afflicts more than three million people in the United States. It characterized by numbness, tingling, and burning, sharp, shooting or other painful sensations,…
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…